PART 1 (of 4)
To kick off Auckland Startup Week, Bridgewest Ventures New Zealand hosted the fourth annual Impactful Innovation Conference at Pipiri Lane Event Space on the Tāmaki Makaurau waterfront. Each year, the conference brings together global leaders, founders, and deep-tech experts to share their experiences and ideas about the future of innovation.
The morning began with some much-needed coffee and breakfast, kindly provided by Acclime, before we were officially welcomed by Mayor Wayne Brown. A big supporter of Auckland's startup community, Mayor Brown has been championing local innovation through his '100 Days of Startups' initiative, complete with matching T-shirts!
This year, we heard from nine speakers across three sectors: Human Health, Planetary Health, and Frontier Technology. Each session was followed by a fireside chat, giving guests the chance to ask questions and dig a little deeper into the speakers' experiences. Throughout the day, nine Kiwi founders also pitched their startups to an experienced and well-connected audience as part of the BNZ Spotlight Presentations.
There was a huge amount of valuable advice shared throughout the day, so much that we’ve turned it into a four-part blog series!
In this first part, we’re diving into the Human Health session, where Dr Kelli Luginbuhl, Oliver Hardick, and Dr Stuart Chambers shared their experiences and lessons on turning scientific discoveries into successful businesses.
Dr. Kelli Luginbuhl on Unlearning the Scientist Mindset
Taking science from the lab into the world requires more than a promising discovery. For Dr Kelli Luginbuhl, it also means knowing which scientific instincts to hold onto and which to unlearn.
Drawing on her own entrepreneurial journey and work with hundreds of early-stage founders, Kelli shared two habits scientists need to unlearn, alongside three strengths they should carry into entrepreneurship.
The first habit to unlearn is the pursuit of endlessly improving the science, or in Kelli's words, "The science is never done." While this drive is natural for researchers, it can become a trap for founders. There will always be ways to refine a technology, but knowing when to stop perfecting and start commercialising is essential.
The second is the belief that everything can be learned from the literature. Building a business requires stepping outside the lab and speaking directly to the people whose problems you're trying to solve. Understanding what customers actually need, rather than relying on assumptions, is where some of the most valuable learning happens.
But becoming an entrepreneur does not mean fully leaving your scientific mindset behind. Kelli encouraged researchers to hold onto their curiosity, just redirect it towards customers and markets. That same curiosity is especially useful when facing rejection. Rather than being discouraged by sceptics, she encouraged founders to lean into those conversations, as they can often provide the richest learning opportunities.
Her final lesson was perhaps the most important: "Nothing hard is ever done alone." Building a company takes far more than just scientific expertise, and Kelli encouraged founders to surround themselves with people who are equally passionate about manufacturing, operations, sales, and the other parts of running a business. When people share a genuine belief in what you're trying to achieve, you'd be surprised how many are willing to help make it happen.
Oliver Hardick on Building a Business with the End in Mind
Having sat on every side of the table as an academic founder, scaling CEO, and venture investor, Oliver Hardick brought a unique perspective on deep-tech commercialisation. Joining us all the way from the UK, Ollie shared his advice on building a successful startup, with one central message: build your business with the end in mind.
He began by emphasising the importance of relationships and trust. Whether dealing with investors, board members, or commercial partners, founders should make themselves easy to trust. Be engaged, know the details of your business, share difficult news early, welcome constructive criticism, and follow through on your commitments. As Ollie put it, "A board or investor should never be surprised by a problem you already knew about."
He also spoke about balancing ambition with validation. Investors want to see big opportunities, but an exciting vision means little without evidence that customers actually want what you're building. Pilot programmes, customer conversations, and credible early users all help turn an ambitious story into a believable investment proposition. His advice was simple: "Make it easy to believe." To put this into perspective, Ollie explained that of roughly 2,000 investment opportunities reviewed each year, only around 50 reach meaningful due diligence, and just 10 receive investment. Founders therefore need to demonstrate why their business deserves to be one of those few.
He encouraged founders to work backwards from their desired outcome. Does your product solve a valuable problem? Will customers pay for it? Do you have the right people and evidence to reach the next stage? And is the capital you're raising actually funding meaningful progress?
Rather than simply asking what needs to be done next, Ollie left founders with a more useful question: "What is the next piece of work that makes the end more likely?"
Dr Stuart Chambers on Capturing the Value of Scientific Discovery
The final speaker in Human Health was Dr Stuart Chambers, Entrepreneur in Residence at the University of Otago, who brought over 25 years of experience in stem-cell research and commercialisation. Having worked in both academia and industry, Stuart shared how scientific discoveries can become valuable businesses, and why protecting intellectual property early is so important.
Stuart’s interest in stem cells began from a young age when he learned geckos could regrow their tails. That curiosity eventually led him into stem-cell research, where he developed techniques to turn stem cells into specific types of neurons. This research has contributed to the development of therapies for conditions such as Parkinson's disease and epilepsy. Stuart was the founding stem cell scientist at Neurona Therapeutics, a company recently acquired by UCB for USD$1.15 billion, demonstrating the enormous potential of translating academic research into real-world treatments.
The key point of Stuart's talk was about the importance of capturing intellectual property before it's too late. He explained that some of the most important decisions affecting a startup's future value happen long before investors become involved, often while the technology is still being developed at university.
Scientists are naturally eager to publish and share their discoveries, but doing so before protecting the underlying IP can jeopardise future commercial opportunities. Stuart encouraged researchers to disclose inventions to their university's commercialisation team before publishing or presenting their work publicly. This allows patent protection to be considered early, creating a stronger foundation for future investment, licensing, or company formation.
He finished by emphasising that capturing IP doesn't necessarily require much additional work from researchers, just an understanding of the right order of operations. With growing emphasis on translating New Zealand research into commercial outcomes, getting these early decisions right can create tremendous value, whether the end goal is building a startup or licensing a technology to an established company.
Human Health Wrap-up
While each speaker approached commercialisation from a different perspective, their advice pointed towards a common lesson: successful deep-tech companies are built by looking beyond the science.
Whether it's understanding what customers actually need, building trust with investors, or protecting intellectual property early, the decisions founders make along the way can be just as important as the technology itself.
Coming up in Part 2: We turn our attention to Planetary Health, where Dr Kathryn Meng, Fraser Hodgson, and Juliana Garaizar explore the investment, regulatory, and geopolitical forces shaping the future of cleantech innovation.
Harriet Cook
Intern at Bridgewest Ventures New Zealand. Connect on LinkedIn.